At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Liposomal Doxorubicin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV/II Trial With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab in Patients With Metastatic Breast Cancer With Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2)/Neu
In Brief
A Phase 2 clinical trial evaluating Liposomal Doxorubicin, Cyclophosphamide, and 1 other intervention for Breast Cancer. Completed, enrolled 49 participants across 12 sites.
Detailed Summary
Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSpain
CollaboratorsSchering-Plough
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartFeb 2006
Primary CompletionJul 2008
Study CompletionJul 2009
TodayJul 2026
First PostedNov 28, 2005
Enrollment StartFeb 15, 2006
Primary CompletionJul 1, 2008
Study CompletionJul 14, 2009
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.6 years ago
Interventions
Liposomal Doxorubicindrug
Cyclophosphamidedrug
Trastuzumabdrug